Archive

Past newsletters of MDDR.

• Wednesday, 5 August 2026

  Medicare reform for rural GPs, Stable high-dose vitamin B6 sales, OPTIRAY Imaging recall issued

  Rural GPs face increasing challenges from a Medicare system that favours short consultations, according to testimony at a recent Parliamenta

• Tuesday, 4 August 2026

  RACGP criticises home care funding, Roadmap for international medical, Outreach scholarships for LARC training

  The RACGP has labelled the Federal Government's Support at Home program a ‘missed opportunity’ for failing to leverage GPs' clinical experti

• Monday, 3 August 2026

  340B rebate plan reintroduced, Cyclospora management challenges, Cambodia achieves HIV treatment targets

  The Trump administration announced plans to implement rebates in the 340B drug discount program starting in 2027. This marks the second atte

• Sunday, 2 August 2026

  Gender pay gap for female GPs, FDA panel backs melanoma treatment, Novo Nordisk heart drug trial fails

  Women GPs in Australia continue to face a significant gender pay gap, with average incomes reported at $171,087 for female GPs compared to $

• Saturday, 1 August 2026

  Victorian GPs advocate at Parliament, Digital app aids chronic pain management, High-THC cannabis safety concerns

  GPs conducted health checks and advocated for general practice directly with Victorian politicians during the GPs@Parliament event. The init

• Friday, 31 July 2026

  Telehealth rules amid fuel shortages, Depemokimab approved for asthma, New blood test for dementia detection

  Peak medical organisations, including the AMA and RACGP, have urged the government to adjust Medicare’s telehealth service limits in respons

• Thursday, 30 July 2026

  RACGP compliance risks in reforms, New data on miscarriage prevalence, Rural health training program overhaul

  The RACGP expressed concerns over the proposed Health Insurance Amendment Act, which could impose fines on GP clinics falsely claiming parti

• Wednesday, 29 July 2026

  Itvisma gene therapy approved in EU, Orlistat kidney injury warnings, Rextovy nasal spray for overdoses

  The European Medicines Agency has authorised Itvisma, a gene therapy for treating spinal muscular atrophy (SMA) in patients aged 2 years and

• Tuesday, 28 July 2026

  Peptide prescribing guidance update, Global taskforce on skin bleaching, Ventolin shortage until late 2028

  The Medical Board of Australia is developing new guidance for prescribing off-label, unapproved, and compounded medicines in response to the

• Monday, 27 July 2026

  Salim Yusuf's heart disease impact, History of health travel practices, Investing in adolescent health

  Heart disease remains the leading cause of premature death globally. A new biography, 'Climbing Mountains: The Journey to Beat the World's B